Overview
EDIT market data
Price History
EDIT price chart
Valuation & Profitability
No Valuation Data Yet
Alpha Vantage and Twelve Data both returned no valuation metrics for EDIT. Check back after the next daily valuation refresh — this symbol may be new, delisted, or temporarily unavailable from both providers.
Company news
Lyora Therapeutics Launches With Seed Funding to Propel Its Biologically Validated Pipeline of Genetic Medicines to Treat Inherited Retinal DiseasesGlobenewswire Inc · Jul 14, 2026, 3:15 PM
Gene Editing Therapeutics: Transforming Biopharmaceuticals with 12.5% CAGR Growth ForecastGlobenewswire Inc · Jul 3, 2026, 11:00 AM
Global CRISPR-Based Drug Development Platforms Market to Reach USD 0.79 Billion by 2031: Precision Medicine and Gene Therapy Drive GrowthGlobenewswire Inc · Jul 3, 2026, 11:00 AM
Rivian Automotive, Tenax Therapeutics, Robinhood And Other Big Stocks Moving Higher On ThursdayBenzinga · Jul 2, 2026, 2:30 PM
Abercrombie & Fitch Upbeat Q1 Earnings, Joins Digital Turbine, Dycom Industries And Other Big Stocks Moving Higher On WednesdayBenzinga · May 27, 2026, 2:55 PM
8-K filing — Editas Medicine, Inc. (EDIT)SEC EDGAR · May 26, 2026, 8:42 PM
Editas Medicine Prices $125M Public Offering Of 55.6M Shares And Warrants At $2.25 EachBenzinga · May 26, 2026, 1:08 PM
Editas Medicine Launches Public Stock Offering to Raise CapitalBenzinga · May 26, 2026, 10:19 AM
Editas Reports Cholesterol-Lowering Results for Experimental Gene TherapyBenzinga · May 26, 2026, 10:11 AM
Editas Medicine Announces New Preclinical Data Supporting Continued Advancement Of Its In Vivo Development Candidate, EDIT-401, And Its Potential As A One-Time Treatment For HyperlipidemiaBenzinga · May 14, 2026, 10:09 AM